Oramed (ORMP) CFO Avraham Gabay gains 19,000 shares via PSU vesting

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay reported the vesting of 19,000 performance stock units into common shares. The PSUs were granted on December 31, 2025 and vested on January 22, 2026 after Oramed’s common stock reached a specified price per share.

Each PSU converted into one share of common stock, and the shares were received for no cash consideration. Following this transaction, Gabay directly beneficially owns 649,256 shares of Oramed common stock.

Insider Trade Summary

19,000 shares exercised/converted

Mixed 2 txns

Insider Gabay Avraham

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Performance Stock Units	19,000	$0.00	--
Exercise	Common Stock	19,000	$0.00	--

Holdings After Transaction: Performance Stock Units — 0 shares (Direct); Common Stock — 649,256 shares (Direct)

Footnotes (1)

Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting. Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

Form 4 Insider Transactions: What Each Field Means →

01/29/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gabay Avraham

(Last)

(First)

(Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/22/2026		M		19,000⁽¹⁾	A	$0⁽¹⁾	649,256	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance Stock Units	⁽¹⁾	01/22/2026		M			19,000	⁽²⁾	⁽²⁾	Common Stock	19,000	$0	0	D

Explanation of Responses:

1. Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

2. Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

	/s/ Avraham Gabay	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Oramed (ORMP) CFO Avraham Gabay report?

Avraham Gabay reported the vesting of 19,000 performance stock units into Oramed common stock. The PSUs converted on January 22, 2026 after a stock price condition was met, and the resulting shares were received for no cash consideration.

How many Oramed (ORMP) shares does CFO Avraham Gabay own after this Form 4?

After this transaction, Avraham Gabay beneficially owns 649,256 shares of Oramed common stock. This reflects the addition of 19,000 shares received from vesting performance stock units, all held in direct ownership according to the Form 4 disclosure.

What are performance stock units in the Oramed (ORMP) CFO’s Form 4?

In this filing, each performance stock unit represents a contingent right to receive one share of Oramed common stock. The units vest only when specified performance criteria, including a stock price target, are achieved, triggering delivery of the underlying shares.

When did the Oramed (ORMP) CFO’s performance stock units vest?

The performance stock units granted to Oramed’s CFO on December 31, 2025 vested on January 22, 2026. Vesting occurred when Oramed’s common stock achieved a specified price per share, which satisfied the PSU performance condition described in the Form 4 footnotes.

Did Oramed (ORMP) CFO Avraham Gabay pay for the vested shares?

No, the shares of Oramed common stock received from the PSU vesting were issued for no consideration. The Form 4 states that the 19,000 shares were delivered upon vesting of the performance stock units without any cash payment by the reporting person.